Keyphrases
2-dose
33%
4-fold
16%
6-month Follow-up
16%
Age of Vaccination
16%
Antibody Titer
16%
Antigen Dose
33%
China
16%
Clinical Outcomes
16%
Fold Increase
16%
Geometric Mean Titer
33%
H7N9
16%
H7N9 Influenza Virus
100%
H7N9 Vaccine
100%
Hemagglutination Inhibition
33%
Hemagglutination Inhibition Antibody
16%
Hemagglutinin
16%
High Morbidity
16%
High Mortality
16%
Human Infection
16%
Immunogenicity
16%
Influenza A
16%
Intramuscularly
16%
Local Symptoms
16%
MF59 Adjuvant
100%
Neutralizing Antibody Assay
16%
Nominal Dose
16%
Non-associated
16%
Old Age
16%
Phase II Trial
16%
Post-vaccination Symptoms
33%
Randomized Clinical Trial
100%
Randomized Double-blind
16%
Seasonal Influenza Vaccination
16%
Serious Adverse Events
33%
Seroconversion
100%
Serological Response
100%
Titer
16%
Whole-cell Vaccine
16%
Medicine and Dentistry
Adjuvant
33%
Adverse Event
33%
Avian Influenza
100%
Hemagglutination Inhibiting Antibody
16%
Hemagglutination Inhibition
33%
Hemagglutinin
16%
Immunoassay
16%
Immunogenicity
16%
Inactivated Virus Vaccine
16%
Infection
16%
Influenza A
16%
Influenza A (H7N9)
100%
Influenza A Virus (H7N9)
83%
Influenza Vaccination
16%
Mifamurtide
100%
Neutralizing Antibody
16%
Randomized Clinical Trials
100%
Seasonal Influenza
16%
Seroconversion
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adjuvant
33%
Adverse Event
33%
Avian Influenza
100%
Hemagglutination Inhibiting Antibody
16%
Hemagglutinin
16%
Immunoassay
16%
Immunogenicity
16%
Inactivated Virus Vaccine
16%
Infection
16%
Influenza A
16%
Influenza A (H7N9)
100%
Influenza A Virus (H7N9)
83%
MF59
100%
Neutralizing Antibody
16%
Randomized Clinical Trial
100%
Seasonal Influenza
16%
Immunology and Microbiology
Adjuvant
28%
Antibody Titer
14%
Aves
100%
Hemagglutination Inhibiting Antibody
14%
Hemagglutination Inhibition
28%
Hemagglutinin
14%
Immunoassay
14%
Immunogenicity
14%
Inactivated Virus Vaccine
14%
Infection
14%
Influenza
100%
Influenza A Virus (H7N9)
100%
MF59
100%
Neutralizing Antibody
14%
Seroconversion
85%
Titer
42%